Jim Cramer: A better way to invest in the Covid-19 vaccine gold rush Description video: Instead of making a risky bet on vaccine developers, \”Mad Money\” host Jim Cramer makes recommendations of companies supplying research equipment. Subscribe to CNBC PRO […]
Jim Cramer: A better way to invest in the Covid-19 vaccine gold rush
Instead of making a risky bet on vaccine developers, \”Mad Money\” host Jim Cramer makes recommendations of companies supplying research equipment. Subscribe to CNBC PRO for access to investor and analyst insights: https://cnb.cx/2Vtntx6 \n\n» Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision\n» Subscribe to CNBC: https://cnb.cx/SubscribeCNBC\n» Subscribe to CNBC Classic: https://cnb.cx/SubscribeCNBCclassic\n \nTurn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide.\n \nConnect with CNBC News Online\nGet the latest news: http://www.cnbc.com/\nFollow CNBC on LinkedIn: https://cnb.cx/LinkedInCNBC\nFollow CNBC News on Facebook: https://cnb.cx/LikeCNBC\nFollow CNBC News on Twitter: https://cnb.cx/FollowCNBC\nFollow CNBC News on Instagram: https://cnb.cx/InstagramCNBC\n \nFor info on the best credit cards go to CNBC Select: \nhttps://www.cnbc.com/select/best-credit-cards/ \n\n#CNBC\n#CNBCTV
Investors anticipating COVID-19 vaccine
Investors awaiting the release of the COVID-19 vaccine are starting to buy up shares in banks and industrial companies in anticipation of a surge in consumer confidence. However, many market participants remain fearful of risks in sectors devastated by the pandemic..
The emergence of any preventative drug is seen as the best chance to stop the coronavirus, which has killed 1.2 million people, and is a major concern for financial managers awaiting the next major market shift..
As the hype around the U.S. election subsides, investors brace for some good news about vaccines they think is just a matter of time..
«This will change a lot. When we get the vaccine, all pent-up demand will spill out.», – said Stuart Oakley, Head of Cash Trading at Nomura in London.
Of the approximately 45 vaccines in human trials, Pfizer projects, AstraZeneca and Moderna viewed as the most promising for regulatory approval this year.
Binai Chandgotia, a Hong Kong portfolio manager at Principal Global Investors noted that banks would benefit from increased economic activity and would be helped if bond yields rose. He also advises paying attention to the securities of small companies on the Hong Kong and Singapore exchanges if trade and tourism begin to gain momentum..
Brian Jacobsen, senior investment strategist at Wells Fargo Asset Management in Wisconsin, said industry offers a wide range of opportunities to rebuild confidence in areas such as construction and aviation.
Deutsche Bank operates «vaccine basket» of Singapore dollars and Thai baht, which are believed to benefit from increased trade and tourism, versus the Philippine peso, which is weighted by increased imports.
Industrial enterprises rallied with the broader market this month but lagged well behind global stocks gaining around 5% this year. Baht has also recently risen against the peso.